they pulled my message too when I wrote about how SNY/Mnkd held off PR and advertisement until insiders will have accumulated enough shares. There is something strange about this stock; there is alot going on in the background yet extreme silence in the public.
this delay in buyout may also have some ties to current studies. Perhaps new results will show better HbA1C than previous studies, waiting for better results and better BO price. This may just be a ploy to buy time; hence, the slow launch to not consume too much money, rather leave it to the buyer.
Al Mann desparately wants a buyout but the price wasn't right; he's already assuming leader position at EYES. Al Mann seems to have alot of connections in France for some reason, SNY is based in France and Eyes is also there. This is the only tie that perhaps clinched SNY deal, otherwise, he might have sold this already to Pfizer.
This contract is one foot in and one foot out, anybody can walk any time. Mnkd opens bids for buyers and SNY isn't willing to put all efforts into selling Afrezza (where is the advertisements?) That $150 million upfront payment is just to guarantee SNY counterbid, in case mnkd decides to sell to other BP's. With 65% stake, if I was SNY, I would go full force and spend a few millions on advertisements and see where I stand on Afrezza. If the perception is good after Afrezza public awareness, then I would offer a buyout for cheap like around $5 billion, in the meantime, I would accumulate cheap shares along this period of silence and uncertainties. If Afrezza is well perceived, i would offer a bigger price tag but it would save me tramendous money, if I had bought alot of mnkd shares; thus, it would still be cheap depending on how many shares of mnkd I have.
This is one relationship full of infidelity and potential back stabbings.
there are currently enough supply to support 1 million subs right? What are they getting from this silent role out? 200 subs after 4 weeks? That is why GS downgrade. Gotta make it known to the public.
I can guarantee anyone the AFrezza will suffer the same faith as Exubera, if there is no advertisement. NO one has even heard of exubera in the medical community; that is how poorly known it was. YOu can't sell something that is known by the public.
those are SNY N. America public relation #s, call them and encourage advertisement. That's the sure way to get blockbuster status. YOu can't silently sell diabetic treatment among 50 other treatments through salesrep; you have to advertise and show the world how unique this product is. The ONLY way to get to $100/sh and above. NO other way; otherwise, this will die the same fatih as Exubera.
The conventional selling of drugs thrue drug reps only works for a CURE or the ONLY treatment option. Afrezza commands attention of the entire world diabetic population of 400 million; the only way to reach this mass media is through TV or internet advertisement. If you guys want to see blockbuster status of AFrezza, call SNY public relation and ask them to advertise. Bombard them with advertisement suggestions.
The banks and hedge funds that have been supporting mnkd are starting to give message to Mnkd management to advertise and do some PR. YOU simply can't sell drugs in the dark without anyone knowing about it. It doesn't matter how great the drug is. UNLESS it is a cure or the ONLY treatment option. I can't believe how stupid these managements are; they are the leaders in biotech and they can't see this.
They upped their holding from 200k shares to 600k shares recently; they are #$%$ that no advertisement or PR was done on Afrezza. How can they sell a blockbuster when no one has heard of?
is it inhale as well? Does it have peak effect in 12 minutes? Then it is not in Afrezza class.
I have stated this many posts before that the way mnkd management behaved since FDA approval has been extremely strange, almost a concerted effort to keep silence and keep the share price down. SNY that just paid off $200 million in 6 months, just to get Afrezza launched sure is doing a really quiet "slow launch". When the market is astounding huge, they have to advertise. This is not the time to save few million$ on TV commercials that could get every diabetics excited and asking for Afrezza. But why no advertisements? Concerted efforts to beat down the price and shake out weak hands, probably for the last time before they advertise.
You can't sell a drug to 400 million diabetics when the docs, pharmacists, and patients haven't heard anything about it. Word of mouth will be slow as snails. Like Viagra, a great selling drug but if they hadn't advertised or became a household name and jokes; it would never have sold as well as it did.
Afrezza is unique to a selection of 50 different diabetic treatments; there needs to be advertisements to separate itself from the rest and become a blockbuster. Advertisement will make patients ask for Afrezza.
It is absolutely stupid to penny pinch when SNY already spent $200 million just to get the drug launched. They will advertise and Afrezza will be sold out the subsequent week, then SNY will announce buyout or/and expand manufacturing facilities.
This slow launch is probably planned to shake out share holders, SNY continues to buy shares, and institutions accumulate. Then bam! advertisements and buyout